Biotechnology

CRISPR Therap

CRISPR Therap released FY2026 Q1 earnings on May 4 (EST), actual revenue USD 1.458 M (forecast USD 4.254 M), actual EPS USD -1.28 (forecast USD -1.2571)

CRISPR Therapeutics Q1 2026 Revenue Misses Expectations

CRISPR Therapeutics Reports Q1 2026 Earnings, Net Loss Decreases, CASGEVY Revenue Growth

CRISPR Therapeutics Announces Expansion of Product Line with Six Data Releases

CRISPR Therapeutics Underperforming but Research Pipeline Shows Potential

CRISPR Therapeutics' Gene Therapy Performs Well but Stock Price Dips

CRISPR Therapeutics plans to issue $350 million convertible senior notes

Versant Venture Management LLC reduced holdings of CRISPR Therapeutics AG in Q3

ARK Investment Increases Biotech Holdings and Reduces Tech Stocks

CRISPR Therapeutics Reports Strong Revenue Growth for Casgevy Gene Therapy

CRISPR Therap released FY2025 Q4 earnings on February 12 (EST), actual revenue USD 864K (forecast USD 4.021M), actual EPS USD -1.371 (forecast USD -1.1542)

CRISPR Therap released FY2025 Annual Earnings on February 12 (EST), actual revenue USD 0 (forecast USD 6.122 M), actual EPS USD 0 (forecast USD -6.1642)

CRISPR Therapeutics Advances Gene Editing Therapies to Clinical Trials

CRISPR Therapeutics AG Outlines 2026 Strategic Focus, Advances Commercialization and Clinical Trials

CRISPR Therapeutics AG CFO Sells Company Stock

CRISPR Therapeutics Quarterly Earnings Beat Expectations but Revenue Misses, Stock Rises

St. Jude Children's Research Hospital Develops New Technology to Solve CRISPR Off-target Effects

ARK Invest Adds to CRISPR Therapeutics Shares

ARK Invest Increases Investment in Autonomous Driving and Gene Editing Fields

ARK Investment by Cathie Wood Buys Shares of WeRide and CRISPR Therapeutics

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

CRSP

SBIO

LABU

CRISPR Therapeutics is entering a 'second phase' as it moves beyond the launch of CASGEVY, with plans to generate data from six pipeline programs over the next 12 to 18 months. CEO Sam Kulkarni highlighted the momentum of CASGEVY's rollout and potential pediatric label expansion, which could enhance treatment access. The company is also focusing on cardiovascular and other disease programs, with promising early data on therapies targeting LDL cholesterol and hypertension.

Market Beat

VanEck Biotech ETF

ALPS Medical Breakthrough

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Vertex Pharma

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms

IDNA

ARKG

CRISPR Therapeutics AG (NASDAQ:CRSP) has received an average analyst rating of "Moderate Buy" from eighteen analysts. The stock has two sell, five hold, ten buy, and one strong buy recommendations. The average 12-month price target is $66.06. Recent price targets include TD Cowen's hold rating at $45, Citigroup's buy rating at $82, and Piper Sandler's overweight rating at $110. The stock opened at $54.01, with a 52-week range of $34.87 to $78.48. The company reported a loss of $1.28 EPS for the last quarter and had revenue of $1.46 million.

Proshares Ultra Nasdaq Biotech

Wisdomtree BioRevolution Fund ETF

Invesco Nasdaq Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

Toronto Dominion Bank

Citigroup

Piper Sandler Cos

CITIGROUP INC 6.250 NON CUM SER II PFD WI

CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Moderate Buy" from Analysts

NTLA

Intellia Therapeutics (NASDAQ:NTLA) reported quarterly earnings of ($0.81) per share, exceeding estimates of ($0.92) by $0.11. The company had a revenue of $15.05 million, surpassing expectations of $13.81 million. Intellia's net margin was -609.85% and return on equity was -56.81%. The stock traded up to $14.73, with a market cap of $1.77 billion. Analysts have mixed ratings, with one strong buy, nine buys, ten holds, and three sells. Institutional investors hold 88.77% of the stock, and the company focuses on CRISPR/Cas9 genome editing therapies.

Intellia Therap

Franklin Genomic Adv ETF

Truist Financial

KeyCorp

Goldman Sachs

S&P 500

Virtu Finc

Invesco

Meta Platforms

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

GS Hldg R

Intellia Therapeutics (NASDAQ:NTLA) Announces Earnings Results

CRISPR Therapeutics AG (NASDAQ:CRSP) has seen a decrease in FY2028 earnings per share estimates from Brookline Capital Markets, dropping from $7.44 to $6.91. The company reported a quarterly EPS of ($1.28), missing estimates, with revenue of $1.46 million. Analysts have mixed ratings on the stock, with a consensus rating of "Moderate Buy" and a target price of $64.53. Recent insider sales have occurred, and institutional investors are adjusting their positions in the stock.

Citizens Financial

Morgan Stanley

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

FY2028 EPS Estimates for CRSP Decreased by Analyst

Piper Sandler analyst Edward Tenthoff has reiterated a Buy rating on Crispr Therapeutics AG (CRSP) with a price target of $110.00. Tenthoff, who focuses on the Healthcare sector, has an average return of 7.4% and a 41.31% success rate on his stock recommendations. Additionally, Needham's Gil Blum also issued a Buy rating for Crispr Therapeutics AG today, while RBC Capital maintained a Hold rating yesterday.

Tip Ranks

Health Care Select Sector SPDR

VG Health

Ark Innovation ETF

iShares US Pharma

iShares Global Healthcare

Karyopharm Therap

Moderna

Alnylam Pharma

ROYAL BANK OF CANADA

Crispr Therapeutics AG (CRSP) Gets a Buy from Piper Sandler

Chardan Capital has reiterated a Buy rating on Crispr Therapeutics AG (CRSP) with a price target of $76.00. Analyst Geulah Livshits, a 5-star analyst with a 12.7% average return, highlights a Moderate Buy consensus rating for the stock, with an average price target of $72.33. Livshits also covers other healthcare stocks like Palvella Therapeutics and Iovance Biotherapeutics.

Palvella Therapeutics

Iovance Biotherapeautics

Rocket Pharma

ROCKET PHARMACEUTICALS INC C/WTS 02/09/2026 (TO PUR COM)

Chardan Capital Remains a Buy on Crispr Therapeutics AG (CRSP)

CRISPR Therapeutics AG reported Q1 2026 results with revenue of $1.458M, a net loss of $(122.931) M, and diluted EPS of $(1.28). Revenue increased by 68.5% year-over-year. The company narrowed its net loss from $(135.996) M in Q1 2025. Key highlights include product approvals for CASGEVY, advancements in LNP and SyNTase platforms, and ongoing trials for sickle cell disease and type 1 diabetes. Strategic partnerships with Vertex and Sirius are enhancing co-development efforts. Continued investment in manufacturing and R&D is prioritized across four core franchises.

TradingView

Sirius XM

CRISPR Therapeutics AG 1Q 2026: Revenue $1.458M, EPS $(1.28) — 10-Q Summary

Earnings Watch

CRISPR Therap | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 1.458 M

CRISPR Therap(CRSP.US)